Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes von Ericsson, Åsa, Glah, Divina, Lorenzi, Maria, Jansen, Jeroen P, Fridhammar, Adam

Volltext

Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype von Aronsson, Linus, Ansari, Daniel, Andersson, Bodil, Persson, Ulf, Fridhammar, Adam, Andersson, Roland

Volltext

MRI-only radiotherapy from an economic perspective: Can new techniques in prostate cancer treatment be cost saving? von Persson, Emilia, Svanberg, Niklas, Scherman, Jonas, Jamtheim Gustafsson, Christian, Fridhammar, Adam, Hjalte, Frida, Bäck, Sven, Nilsson, Per, Gunnlaugsson, Adalsteinn, Olsson, Lars E.

Volltext

Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Econ... von Willis, Michael, Fridhammar, Adam, Gundgaard, Jens, Nilsson, Andreas, Johansen, Pierre

Volltext

Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden von Ericsson, Åsa, Fridhammar, Adam

Volltext

Recombinant FVIII replacement products for haemophilia A: An updated valuation by indirect comparison measuring area under the curve von Persson, Sofie, Fridhammar, Adam, Carlsson, Katarina Steen, Berntorp, Erik

Volltext

The implementation of a noninvasive lymph node staging von Fridhammar, Adam, Bendahl, Pär-Ola, Dihge, Looket, Huss, Linnea, Ohlsson, Mattias, Nilsson, Kristoffer, Skarping, Ida

Volltext

1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada von LIU, AIDEN R., BECH, PETER G., FRIDHAMMAR, ADAM, NILSSON, ANDREAS, WILLIS, MICHAEL, NUHOHO, SOLOMON

Volltext

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer von Skarping, Ida, Nilsson, Kristoffer, Dihge, Looket, Fridhammar, Adam, Ohlsson, Mattias, Huss, Linnea, Bendahl, Pär-Ola, Steen Carlsson, Katarina, Rydén, Lisa

Volltext

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting von Stafford, Sara, Bech, Peter G., Fridhammar, Adam, Miresashvili, Nino, Nilsson, Andreas, Willis, Michael, Liu, Aiden

Volltext

Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge von Altunkaya, James, Li, Xinyu, Adler, Amanda, Feenstra, Talitha, Fridhammar, Adam, Keng, Mi Jun, Lamotte, Mark, McEwan, Phil, Nilsson, Andreas, Palmer, Andrew J., Quan, Jianchao, Smolen, Harry, Tran-Duy, An, Valentine, William, Willis, Michael, Leal, José, Clarke, Philip

Volltext

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting von Eliasson, Björn, Ericsson, Åsa, Fridhammar, Adam, Nilsson, Andreas, Persson, Sofie, Chubb, Barrie

Volltext

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting von Stafford, Sara, Bech, Peter G., Fridhammar, Adam, Miresashvili, Nino, Nilsson, Andreas, Willis, Michael, Liu, Aiden

Volltext

Introducing PIONEER: a project to harness big data in prostate cancer research von Omar, Muhammad Imran, Roobol, Monique J., Ribal, Maria J., Abbott, Thomas, Agapow, Paul-Michael, Araujo, Sonia, Asiimwe, Alex, Auffray, Charles, Balaur, Irina, Beyer, Katharina, Bernini, Chiara, Bjartell, Anders, Briganti, Alberto, Butler-Ransohoff, John-Edward, Campi, Riccardo, Cavelaars, Marinel, De Meulder, Bertrand, Devecseri, Zsuzsanna, Voss, Marc Dietrich, Dimitropoulos, Konstantinos, Evans-Axelsson, Susan, Franks, Billy, Fullwood, Louise, Horgan, Denis, Smith, Emma Jane, Kiran, Amit, Kivinummi, Kati, Lambrecht, Mark, Lancet, Doron, Lindgren, Peter, MacLennan, Sara, MacLennan, Steven, Nogueira, Maria Manuela, Moen, Fredrik, Moinat, Maxim, Papineni, Kishore, Reich, Christian, Reiche, Kristin, Rogiers, Stijn, Sartini, Claudio, van Bochove, Kees, van Diggelen, Femke, Van Hemelrijck, Mieke, Van Poppel, Hein, Zong, Jihong, N’Dow, James

Volltext

38 - Cost Effectiveness of Oral Semaglutide 14 mg Vs Empagliflozin 25 mg in Canada von Liu, Aiden, Bech, Peter, Fridhammar, Adam, Nilsson, Andreas, Willis, Michael, Nuhoho, Solomon

Volltext

The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development von Fridhammar, Adam, Axelsson, Ulrika, Persson, Ulf, Bjartell, Anders, Borrebaeck, Carl A. K.

Volltext

Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be? von Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J, Venderbos, Lionne D F, Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J, MacLennan, Steven, Omar, Muhammad Imran, Van Hemelrijck, Mieke

Volltext

Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research von Omar, Muhammad Imran, Roobol, Monique J., Ribal, Maria J., Abbott, Thomas, Agapow, Paul-Michael, Araujo, Sonia, Asiimwe, Alex, Auffray, Charles, Balaur, Irina, Beyer, Katharina, Bernini, Chiara, Bjartell, Anders, Briganti, Alberto, Butler-Ransohoff, John-Edward, Campi, Riccardo, Cavelaars, Marinel, De Meulder, Bertrand, Devecseri, Zsuzsanna, Voss, Marc Dietrich, Dimitropoulos, Konstantinos, Evans-Axelsson, Susan, Franks, Billy, Fullwood, Louise, Horgan, Denis, Smith, Emma Jane, Kiran, Amit, Kivinummi, Kati, Lambrecht, Mark, Lancet, Doron, Lindgren, Peter, MacLennan, Sara, MacLennan, Steven, Nogueira, Maria Manuela, Moen, Fredrik, Moinat, Maxim, Papineni, Kishore, Reich, Christian, Reiche, Kristin, Rogiers, Stijn, Sartini, Claudio, van Bochove, Kees, van Diggelen, Femke, Van Hemelrijck, Mieke, Van Poppel, Hein, Zong, Jihong, N’Dow, James

Volltext